These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35862378)

  • 41. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial.
    Lou Y; Liu L; Yao H; Hu X; Su J; Xu K; Luo R; Yang X; He L; Lu X; Zhao Q; Liang T; Qiu Y
    Eur J Pharm Sci; 2021 Feb; 157():105631. PubMed ID: 33115675
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real-world Experience with Favipiravir for Treatment of COVID-19 among Indian Healthcare Professionals.
    Tiwaskar M; Dhar R; Talwar D; Ansari A; Lakhe M; Panchal S; Bhagat S; Patil S; Barkate H
    J Assoc Physicians India; 2022 Dec; 69(12):11-12. PubMed ID: 35057588
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The efficacy of Siddha Medicine, Kabasura Kudineer (KSK) compared to Vitamin C & Zinc (CZ) supplementation in the management of asymptomatic COVID-19 cases: A structured summary of a study protocol for a randomised controlled trial.
    Natarajan S; Anbarasi C; Sathiyarajeswaran P; Manickam P; Geetha S; Kathiravan R; Prathiba P; Pitchiahkumar M; Parthiban P; Kanakavalli K; Balaji P
    Trials; 2020 Oct; 21(1):892. PubMed ID: 33109252
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A review on favipiravir: the properties, function, and usefulness to treat COVID-19.
    Hashemian SM; Farhadi T; Velayati AA
    Expert Rev Anti Infect Ther; 2021 Aug; 19(8):1029-1037. PubMed ID: 33372567
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Favipiravir-induced fever in coronavirus disease 2019: A report of two cases.
    Takoi H; Togashi Y; Fujimori D; Kaizuka H; Otsuki S; Wada T; Takeuchi Y; Abe S
    Int J Infect Dis; 2020 Dec; 101():188-190. PubMed ID: 32992014
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy D glucose in treating COVID-19.
    Kulkarni P; Padmanabhan S
    Biotechnol Lett; 2022 Jul; 44(7):831-843. PubMed ID: 35608787
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence of Micronutrient Deficiencies in Patients Hospitalized with COVID-19: An Observational Cohort Study.
    Voelkle M; Gregoriano C; Neyer P; Koch D; Kutz A; Bernasconi L; Conen A; Mueller B; Schuetz P
    Nutrients; 2022 Apr; 14(9):. PubMed ID: 35565831
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).
    McCullough PA
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32967849
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial.
    Thomas S; Patel D; Bittel B; Wolski K; Wang Q; Kumar A; Il'Giovine ZJ; Mehra R; McWilliams C; Nissen SE; Desai MY
    JAMA Netw Open; 2021 Feb; 4(2):e210369. PubMed ID: 33576820
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study.
    Annweiler G; Corvaisier M; Gautier J; Dubée V; Legrand E; Sacco G; Annweiler C
    Nutrients; 2020 Nov; 12(11):. PubMed ID: 33147894
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?
    Ozsurekci Y; Oygar PD; Gürlevik SL; Kesici S; Ozen S; Kurt Sukur ED; Gülhan B; Topaloglu R; Bayrakci B; Cengiz AB
    Pediatr Nephrol; 2021 Nov; 36(11):3771-3776. PubMed ID: 34021797
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease.
    AlQahtani M; Kumar N; Aljawder D; Abdulrahman A; Mohamed MW; Alnashaba F; Fayyad MA; Alshaikh F; Alsahaf F; Saeed S; Almahroos A; Abdulrahim Z; Otoom S; Atkin SL
    Sci Rep; 2022 Mar; 12(1):4925. PubMed ID: 35322077
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High-dose versus standard-dose vitamin D supplementation in older adults with COVID-19 (COVIT-TRIAL): A multicenter, open-label, randomized controlled superiority trial.
    Annweiler C; Beaudenon M; Gautier J; Gonsard J; Boucher S; Chapelet G; Darsonval A; Fougère B; Guérin O; Houvet M; Ménager P; Roubaud-Baudron C; Tchalla A; Souberbielle JC; Riou J; Parot-Schinkel E; Célarier T;
    PLoS Med; 2022 May; 19(5):e1003999. PubMed ID: 35639792
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of micronutrient supplements on influenza and other respiratory tract infections among adults: a systematic review and meta-analysis.
    Abioye AI; Bromage S; Fawzi W
    BMJ Glob Health; 2021 Jan; 6(1):. PubMed ID: 33472840
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Factors associated with anti-SARS-CoV-2 antibody titres 3 months post-vaccination with the second dose of BNT162b2 vaccine: a longitudinal observational cohort study in western Greece.
    Parthymou A; Habeos EE; Habeos GI; Deligakis A; Livieratos E; Marangos M; Chartoumpekis DV
    BMJ Open; 2022 May; 12(5):e057084. PubMed ID: 35589363
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Virological and genomic analysis of SARS-CoV-2 from a favipiravir clinical trial cohort.
    Suzuki M; Imai T; Sakurai A; Komoto S; Ide T; Lim CK; Shintani A; Doi Y; Murata T
    J Infect Chemother; 2021 Sep; 27(9):1350-1356. PubMed ID: 34176716
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial.
    Bosaeed M; Alharbi A; Mahmoud E; Alrehily S; Bahlaq M; Gaifer Z; Alturkistani H; Alhagan K; Alshahrani S; Tolbah A; Musattat A; Alanazi M; Jaha R; Sultana K; Alqahtani H; Al Aamer K; Jaser S; Alsaedy A; Ahmad A; Abalkhail M; AlJohani S; Al Jeraisy M; Almaziad S; Albaalharith N; Alabdulkareem K; Alshowair A; Alharbi NK; Alrabiah F; Alshamrani M; Aldibasi O; Alaskar A
    Clin Microbiol Infect; 2022 Apr; 28(4):602-608. PubMed ID: 35026375
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
    González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
    Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Junqueira-Kipnis AP; Dos Anjos LRB; Barbosa LCS; da Costa AC; Borges KCM; Cardoso ADRO; Ribeiro KM; Rosa SBA; Souza CC; das Neves RC; Saraiva G; da Silva SM; Silveira EA; Rabahi MF; Conte MB; Kipnis A
    Trials; 2020 Oct; 21(1):881. PubMed ID: 33106170
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-dose vitamin D versus placebo to prevent complications in COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial (CARED-TRIAL).
    Mariani J; Tajer C; Antonietti L; Inserra F; Ferder L; Manucha W
    Trials; 2021 Feb; 22(1):111. PubMed ID: 33522946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.